MedTrace Logo

Baseline Sleep Apnea Study #2

NCT04599803 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2022-10-05

Study results available
· View outcomes & findings →

Summary

This is a single group, unblinded, prospective clinical study. This study seeks to understand patient diagnostic and treatment journey and positive airway pressure (PAP) therapy compliance for Verily Sleep Apnea (VSA) program/app users. Participants will enroll remotely and may undergo a home sleep test (HST). Upon confirmation of obstructive sleep apnea (OSA) and prescription of PAP therapy, the participant will begin using the VSA app to supplement PAP treatment. After 90 days of active participation, the participant will be given instructions for follow-up care, as indicated.

Conditions

  • Obstructive Sleep Apnea of Adult

Interventions

DEVICE

Verily Sleep Apnea (VSA) Program/App

The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.

Sponsors & Collaborators

  • Verily Life Sciences LLC

    lead INDUSTRY

Principal Investigators

  • Shannon Sullivan, MD · Verily Life Sciences LLC

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-08
Primary Completion
2021-03-30
Completion
2021-03-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04599803 on ClinicalTrials.gov